Business Context and Reporting Period
This Form 8-K is filed by Eyenovia, Inc. (not Hyperion Defi, Inc.) on August 22, 2024, reporting events occurring on August 20 and 21, 2024. The company is a Delaware corporation trading on the Nasdaq Capital Market under the symbol EYEN. The filing primarily addresses the entry into a material definitive agreement regarding a private placement of common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of common stock.
- Shares Sold: 12,850,000 shares.
- Offering Price: $0.40 per share.
- Gross Proceeds: Approximately $5.14 million.
- Placement Agent: Dawson James Securities, Inc.
- Expected Closing Date: On or about August 22, 2024.
Use of Proceeds: The company intends to use net proceeds to fund commercialization activities for products Mydcombi and clobetasol propionate, complete the CHAPERONE pediatric myopia clinical study, and for working capital. Proceeds may also be used to repay amounts outstanding under a Loan and Security Agreement with Avenue Capital Management II, L.P.
Material Changes and Outlook
This filing represents a material change in the company's capital structure through the issuance of new equity. The transaction is being made pursuant to an effective registration statement on Form S-3 (No. 333-261638). The filing includes forward-looking statements regarding the completion of the offering, the use of proceeds, and potential regulatory approvals for product candidates. Management notes that actual outcomes may differ materially from expectations due to risks and uncertainties.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting placement fees and expenses.
- Review the specific terms of the Loan and Security Agreement with Avenue Capital Management II, L.P. to assess the extent of debt repayment.
- Monitor the progress of the CHAPERONE pediatric myopia clinical study and commercialization timelines for Mydcombi and clobetasol propionate.
- Check for any subsequent filings regarding the dilution impact of the 12,850,000 new shares on existing shareholders.